Protalix Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Protalix Biotherapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 11, 2026. The filing serves as a Regulation FD disclosure regarding the release of a corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 8-K. The document solely references the posting of a corporate presentation to the company's website.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, and contingencies are contained within the attached corporate presentation (Exhibit 99.1) but are not summarized in the body of this filing. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other registration statements.
Investor Verification Checklist
- Review the February 2026 Corporate Presentation (Exhibit 99.1) for detailed financial data and strategic updates.
- Verify the company's current cash position and burn rate, as these are not disclosed in this specific filing.
- Confirm the trading status of Common Stock (Symbol: PLX) on NYSE American.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act.